18 May 2013
Keywords: proethics, reports, strong, ph, iii, data, pro-513
Article | 15 January 2007
The USA's ProEthic Pharmaceuticals has reported strong Phase III trial results for PRO-513, its product candidate for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 January 2007
17 May 2013
© 2013 thepharmaletter.com